Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Lymphoma and Apoptosis

Additional Information

Published Date Dec 19, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3718
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Lymphoma and Apoptosis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Apoptosis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Apoptosis.

    To find out more about Triple Analysis: Leukemia, Lymphoma and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
Abbott
Abiogen
Access
Actinium Pharmaceuticals
Advanced Life Sciences
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alexion
Alfa Wassermann
Alfacell
Allos Therapeutics
Alnylam
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Antisoma
Aphios
Apogenix
ApopLogic Pharmaceuticals
Apricus Biosciences
Arca biopharma
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Basilea Pharmaceutica
Bayer
Benitec
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
BioInvent
Biolex
BioLineRx
Biomas
Bionovo
BioSante
Bioton
BioVex
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Cephalon
ChemoCentryx
Chlorogen
Choongwae
Chroma Therapeutics
CJ Corp
Clavis Pharma
Cleveland BioLabs
CombinatoRx
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
CSL
Curacyte
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dong-A
Dr Reddy’s
Dynavax Technologies
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Favrille
Forma Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Glycotope
GPC Biotech
Green Cross
Hanmi
Harbor BioSciences
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intradigm
Introgen Therapeutics
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Johnson & Johnson
KaloBios
Kalypsys
Kanisa
Keryx Biopharmaceuticals
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
MedImmune
Medisyn Technologies
Memgen
Merck & Co
Merck KGaA
MethylGene
Micromet
Mologen
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
Nycomed Pharma
Onconova
Oncothyreon
OSI Pharmaceuticals
Otsuka
OXiGENE
PanaGin
Patrys
Pfizer
Pharmacyclics
PharmaMar
Pharminox
Philogen
PIERIS Proteolab
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prochon Biotech
ProMetic Life Sciences
ProNAi Therapeutics
QLT
Reata Pharmaceuticals
Regeneron
Regulon
Reliance Life Sciences
Rigel
Rosetta Genomics
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Senesco Technologies
Sepal Pharma
Servier
Shenogen
Shire
Sidus
Sigma-Tau
Southern Research Institute
Spirogen
SRI International
Stemline Therapeutics
SuperGen
SuppreMol
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Taxolog
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Tigris Pharmaceuticals
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
Vaccinex
Valeant
ValiRx
VBL Therapeutics
Velacor Therapeutics
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Viralytics
ViroTarg
VM Discovery
XBiotech
Xencor
Yakult Honsha
Yamasa Corporation
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
AEG-35156
alemtuzumab
alvocidib
AME-133
amonafide malate
amrubicin hydrochloride
amsacrine
APG-101
ARQ-197
AS-101
AS-1411
barasertib
bardoxolone methyl
belinostat
bexarotene
bisantrene
bortezomib
bosutinib
brentuximab vedotin
BZL-101
canfosfamide hydrochloride
cenersen
cintredekin besudotox
cladribine
clofarabine
conatumumab
crolibulin
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
denileukin diftitox
dinaciclib
dulanermin
elacytarabine
elliptinium acetate
enocitabine
enzastaurin hydrochloride
epirubicin
everolimus
fosbretabulin tromethamine
galiximab
gataparsen
gemtuzumab ozogamicin
GT-111
HBP-347
HE-3235
histamine dihydrochloride
ibritumomab tiuxetan
idarubicin
idronoxil
imatinib mesilate
imetelstat
inotuzumab ozogamicin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
irinotecan hydrochloride
kahalalide F
lestaurtinib
leukemia vaccine
litronesib
lonaprisan
lumiliximab
mapatumumab
midostaurin
mitoxantrone
MKC-1
mocetinostat
motexafin gadolinium
navitoclax
nilotinib
noscapine
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
Oncohist
panobinostat
PAT-SC1
PBI-1402
PCI-24781
peginterferon alfa-2b
pentostatin
pixantrone
plitidepsin
pralatrexate
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
razoxane
Reditux
retaspimycin
rhIFN-alpha
rituximab
romidepsin
sagopilone
seliciclib
sobuzoxane
SPC-2996
ß-lapachone
SU-6668
tamibarotene
temsirolimus
teniposide
terameprocol
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
triciribine phosphate
TRU-016
volasertib
vosaroxin
XL-147
XL-647
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Apoptosis.
    To find out more about Triple Analysis: Leukemia, Lymphoma and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Learn More


Triple Analysis: Leukemia, Pancreatic Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Lymphoma and Peptides
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the compound strategy of Peptides. Learn More


Adherens Junction Targeting in Oncology Drug Pipeline Update
BioSeeker Group have identified 277 companies plus partners who are today developing 357 targeting adherens junctions drugs in 1199 developmental projects in cancer across 134 different targets. In addition, there is 1 suspended drug and another 136 drugs where development has been ceased. Learn More